WASHINGTON--A panel of U.S. health advisers on Tuesday narrowly backed a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans ...

Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

Efforts to find an easy, early COVID-19 treatment may have finally panned out An at-home pill against ... an independent review panel decided to stop the global trial early. Merck said it plans ...

A new way to combat COVID-19 Doctors have said they ... group of independent experts to debate and vote on Merck's drug on November 30. That panel narrowly voted 13-10 in favor of authorization ...

The restrictions were expected after an FDA advisory panel only narrowly ... each 40-pill course of treatment. Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow ...

aiming to protect people with mild or moderate COVID-19 from developing severe disease with a drug that can be delivered outside hospital. Merck and partner Ridgeback Biotherapeutics have filed ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...